KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Gains from Investment Securities: 2018-2025

Historic Gains from Investment Securities for Moderna (MRNA) over the last 6 years, with Sep 2025 value amounting to -$14.0 million.

  • Moderna's Gains from Investment Securities fell 112.73% to -$14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.0 million, marking a year-over-year increase of 128.02%. This contributed to the annual value of $197.0 million for FY2024, which is 155.18% up from last year.
  • As of Q3 2025, Moderna's Gains from Investment Securities stood at -$14.0 million, which was up 50.00% from -$28.0 million recorded in Q2 2025.
  • Moderna's Gains from Investment Securities' 5-year high stood at $1.9 billion during Q4 2022, with a 5-year trough of -$332.0 million in Q4 2023.
  • For the 3-year period, Moderna's Gains from Investment Securities averaged around -$19.1 million, with its median value being -$14.0 million (2025).
  • Per our database at Business Quant, Moderna's Gains from Investment Securities surged by 4,600.00% in 2022 and then crashed by 162.86% in 2024.
  • Moderna's Gains from Investment Securities (Quarterly) stood at $354.0 million in 2021, then surged by 450.28% to $1.9 billion in 2022, then plummeted by 117.04% to -$332.0 million in 2023, then spiked by 136.75% to $122.0 million in 2024, then tumbled by 112.73% to -$14.0 million in 2025.
  • Its Gains from Investment Securities stands at -$14.0 million for Q3 2025, versus -$28.0 million for Q2 2025 and -$8.0 million for Q1 2025.